Overall survival in anti-MDA5-positive CADM-ILD patients

(A) The cumulative survival rate at 24 months in anti-MDA5-positive CADM-ILD patients with and without anti-Ro52 antibody. (B) Survival rates stratified according to anti-MDA5 antibody levels. Overall survival rates were determined by Kaplan–Meier test and plus signs represents censored patients.